Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESF sublingual epinephrine in oral allergy syndrome
NCT06527937Phase 2Completed
- Sponsor
- Aquestive Therapeutics
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DESF in anaphylaxis (2 cohorts), sponsored by Aquestive Therapeutics. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve from 0 to 10 minutes and 3 more. Started Jul 2024; status: completed.
02
Drugs
DESF
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT06527937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527937.